
    
      This study is a multi-center, non-comparative, and phase IV clinical trial that evaluates the
      efficacy and safety of conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) in
      patients who have undergone at least one year after liver transplantation and receive
      maintenance therapy with Twice-Daily Tacrolimus.

      Enrolled subjects will take TacroBell slow-release cap.(Once-daily Tacrolimus) for 24 weeks
      and will conduct scheduled tests with four additional visits.
    
  